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Genotyping softwareClinical immunogenetics laboratories performing routine sequencing of human leukocyte antigen (HLA)
genes in support of hematopoietic cell transplantation are motivated to upgrade to next-generation
sequencing (NGS) technology by its potential for cost savings as well as testing accuracy and ﬂexibility.
While NGS machines are available and simple to operate, there are few systems available that provide
comprehensive sample preparation and data analysis workﬂows to complete the process. We report
on the development and testing of the Integrated Genotyping System (IGS), which has been designed
to speciﬁcally address the challenges associated with the adoption of NGS in clinical laboratories. To val-
idate the system for a variety of sample DNA sources, we have tested 336 DNA specimens from whole
blood, dried blood spots, buccal swabs, and lymphoblastoid cell lines. HLA class I and class II genotypes
were derived from amplicon sequencing of HLA-A, -B, -C for exons 1–7 and HLA-DPA1, -DPB1, -DQA1,
-DQB1, -DRB1, -DRB3, -DRB4, -DRB5 for exons 1–4. Additionally, to demonstrate the extensibility of
the IGS to other genetic loci, KIR haplotyping of 93 samples was carried out in parallel with HLA typing
using a workﬂow based on the HLA system. These results are discussed with respect to their applications
in the clinical setting and consequent potential for advancing precision medicine.
 2015 The Authors. Published by Elsevier Inc. on behalf of American Society for Histocompatibility and
Immunogenetics. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).1. Introduction
For over 30 years, clinical immunogenetics laboratories (CILs)
have provided human leukocyte antigen (HLA) typing for use in
the clinical setting. Over 190 HLA typing laboratories are currently
accredited by the American Society for Histocompatibility and
Immunogenetics (ASHI) to carry out HLA typing for clinical appli-
cations, including the thousands of allogeneic hematopoietic cell
transplants (HCT) performed each year around the world [1,2]. In
the absence of an HLA-matched sibling donor, HCT programs man-
date stringent criteria for HLA matching of patients and unrelated
donors [3–5], and the success of unrelated donor HCT has been
amply demonstrated for adults and children with hematologicmalignancies [6–10]. CILs that support unrelated donor HCT pro-
grams require high resolution HLA typing technology.
While capillary electrophoresis (CE)-based dye-terminator
Sanger sequencing is the current gold standard for high resolution
HLA typing in clinical laboratories [11,12], the technology is lim-
ited in throughput, precision, and dynamic range when compared
with NGS systems [13]. Throughput: In the Sanger workﬂow
locus-speciﬁc PCR ampliﬁcation is followed by a dye-terminator
sequencing reaction, which generates a collection of
ﬂuorescently-labeled DNA fragments for each target. Since each
collection of fragments is analyzed in a separate capillary tube,
throughput of the Sanger CE sequencer can be limited to approxi-
mately 48 targets per hour per machine. With current NGS DNA
library preparation techniques, a conservative throughput estimate
for an NGS machine, such as the MiSeq (Illumina, San Diego, CA), is
104 of 600 bp targets per hour [13]. Precision: Sanger CE sequencing
detects signals from both alleles of a heterozygous target, often
generating diploid ambiguities that require extended testing or
statistical inference for resolution. In contrast, NGS methods read
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single pass. Dynamic Range: In Sanger sequencing, the maximum
signal-to-noise ratio is close to 10, meaning that in a sequencing
reaction consisting of two alleles wherein one is represented by
10 times as many dye-terminated fragments as the other (perhaps
as a result of ampliﬁcation bias), only the former allele will be
detected and the minor allele will be lost in noise. The conﬁgura-
tion of NGS makes it possible to simultaneously detect signals that
vary in intensity over a much broader range because the signal
intensity is proportional to the number of clusters, which is rou-
tinely >107 for the MiSeq device. NGS is thus more tolerant of
biases that would otherwise lead to allele drop-off (e.g., preferen-
tial ampliﬁcation, variations in DNA template quality or quantity,
etc.) as well as being extensible to quantitative assays such as chi-
merism testing [14–16].
Recently, a range of NGS systems including reagents and soft-
ware for HLA typing have been reported [17–19]. Long-range PCR
with shotgun sequencing approaches [20–24] are well suited for
research applications that require whole gene sequences.
Alternatively, amplicon approaches [25–28] have been designed
for applications that do not necessarily require complete gene
sequences. These systems can be adapted to either the MiSeq or
the Ion Torrent (Life Technologies, Carlsbad, CA) platforms. Both
systems yield phased data, but the clonal ampliﬁcation and
sequence detection mechanisms of each platform are different.
The MiSeq uses on-chip microﬂuidic cluster generation for clonal
ampliﬁcation with reversible dye-terminator chemistry and optical
detection [29]. The Ion Torrent uses an off-chip bead-based clonal
ampliﬁcation by emulsion PCR or isothermal ampliﬁcation, with
microarray pH-sensing for sequence detection [30–32]. Although
both amplicon and long-range PCR methods have been demon-
strated using the Roche 454 system [33–35], the 454 platform will
apparently be discontinued by the manufacturer in 2016.
Here we describe an amplicon-based NGS approach designed
for a clinical laboratory setting. The Integrated Genotyping
System (IGS) provides a complete package from assay setup
through data analysis and delivery of results. This study reports
high-resolution HLA class I and class II typing of samples frommul-
tiple DNA sources including whole blood, blood spots, buccal
swabs, and cell lines. To demonstrate IGS extensibility to other
immune complex genotyping, KIR gene content and copy number
determination was performed in parallel with HLA typing using
an essentially similar workﬂow. These results were considered
and discussed with respect to design constraints and improvement
opportunities speciﬁc to the clinical laboratory setting.2. Materials and methods
2.1. DNA specimens
190 DNAs puriﬁed from whole blood, 42 dried blood spots, 53
buccal swabs, and 51 lymphoblastoid cell line (LCL) specimens
were tested in parallel. Whole blood specimens were obtained as
puriﬁed DNA from the UCLA Immunogenetics Center (Los
Angeles, CA). DNA was extracted from 6 mm dried blood spots,
from healthy donors, using a scalable protocol [36]. Buccal swabs
from healthy donors were extracted using a ZR-96 Quick-gDNA™
kit (Zymo Research, Irvine CA). DNA was extracted from LCLs, sup-
plied by the International Histocompatibility Working Group
(IHWG, Fred Hutchinson Cancer Research Center, Seattle, WA),
using an isopropanol precipitation method [26].
The IHWG and UCLA panels were chosen for this study in large
part because there are high-resolution genotyping records for most
or all of the HLA class I and class II loci analyzed by the IGS. The
inclusion of well-characterized IHWG specimens known to behomozygous was intended to test the IGS for false positive allele
assignments across multiple HLA loci. While specimens were not
speciﬁcally chosen to represent infrequent or rare HLA alleles,
the UCLA panel, comprising approximately 33% Hispanic, 20%
Caucasian, 20% Black, and 15% Asian (12% with no ethnicity
reported), was intended to provide a diversity of HLA genotypes.
2.2. Targeted amplicon DNA library preparation
All HLA class I and class II genotyping and KIR analysis followed
the manufacturer’s speciﬁcations (Scisco Genetics Inc., Seattle
WA). HLA Version 3.0 IGS kits (Scisco Genetics Inc., Seattle WA)
were used for all HLA typing for this report. Brieﬂy, the HLA and
KIR procedures consisted of amplicon PCR, amplicon pooling, enzy-
matic cleanup, barcoding, barcode pooling, magnetic bead-based
size selection, and quantiﬁcation. Complete exons are sequenced
for HLA genotyping with the exceptions of exon 3 of HLA-DQA1
and exon 2 of -DRB1 and -DRB345, as noted in Table 1.
2.2.1. Amplicon PCR, pooling, and puriﬁcation
The IGS primer sets amplify exons as shown in Table 1. The HLA
class I Version 3.0 includes 9 amplicon PCR reactions generating 42
targets for HLA-A, B, C (2 alleles  3 loci  7 exons). The HLA class
II Version 3.0 includes 8 amplicon PCR reactions generating 48 tar-
gets for HLA-DRB1, -DRB3, -DRB4, -DRB5, -DQA1, -DQB1, -DPA1,
-DPB1 (2 alleles  6 loci  4 exons), depending on the variable
presence of HLA-DRB3, -DRB4 and -DRB5 loci. Amplicon PCR setup
time was approximately 1 h for 96 samples and thermocycling
time is 2.5 h. Subsequent to amplicon PCR, reaction products for
each sample are pooled using volumes appropriate to maintaining
a balance of targets. A mix of exonuclease I (Epicentre, Madison,
WI) and alkaline phosphatase (Roche, Basel, Switzerland) is added
to the pooled products, followed by incubation according to the
manufacturer’s speciﬁcations. The KIR haplotyping kit Version 1.0
was used according to the enclosed protocol (Scisco Genetics Inc.,
Seattle WA).
2.2.2. Barcoding samples
To enable barcoding, DNA linkers containing adaptor sequences
are attached to the puriﬁed amplicon targets and serve as primer
binding sites in a dual-indexing barcode PCR. In this process, all
amplicon targets of each individual sample are barcoded with
the same index sequences so that every sample has a different bar-
code, essentially as previously described [37].
2.2.3. Final puriﬁcation and MiSeq Prep
After barcoding, reaction products from different samples are
pooled together. Each pool undergoes a size selection using
Agencourt AMPure XP beads (Beckman Coulter, Brea, CA) with a
0.7:1 beads to DNA ratio, followed by column puriﬁcation using
a QIAQuick PCR Puriﬁcation kit (Qiagen, Venlo, Limburg,
Netherlands). The puriﬁed pools are quantiﬁed using a
Quant-iT™ PicoGreen dsDNA Assay kit (Life Technologies,
Carlsbad, CA) with Scisco Genetics Quantiﬁcation Standards
(Scisco Genetics Inc., Seattle WA) and pooled into one complete
library that is ready for dilution and denaturation according to
the Illumina MiSeq loading protocol. For this study, MiSeq v3 kits
were used with a loading concentration of 6.5 pM, resulting in a
cluster density of approximately 1000 k/mm2.
2.3. Illumina MiSeq sequencing
The IGS utilizes Illumina MiSeq paired-end
sequencing-by-synthesis (SBS). In this scheme, there are two long
reads of each sequencing cluster, ‘R1’ reads in the 50–30 direction,
and ‘R2’ in the 30–50 direction. R1 and R2 are coupled together as
Table 1
IGS kits.
Type Version Exons covered Notes # Amplicon PCR Rxns # Barcode PCR Rxns
HLA-CI 3.0 1–2–3, 4–5, 6–7 ‘‘X–Y’’ means exons are phased by sequencing 9 3
HLA-CII 3.0 1, 2, 3, 4 Segments not covered: 8 1
DQA1 exon 3: 10 bp (3’ end)
DRB1345 exon 2: 2 bp (5’end) and 6 bp (3’end)
KIR 1.0 3, 4, 5, 9 4 1
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code sequences. In this way, a read pair can be categorized by sam-
ple based on its barcode. Currently, in MiSeq v3 paired-end
sequencing chemistry, each read covers up to 300 bp of a target,
so that 600 bp can be captured by each pair.
We emphasize that the target generation and library prepara-
tion processes described above produce not only target segments,
but also non-target segments such as primer-dimers, chimeric
PCR products [38], and pseudogene sequences. Data corresponding
to non-target sequences, typically <20% of total read pairs, are
identiﬁed and excluded using computational methods incorpo-
rated into the GeMS-Analyzer described below.
A paired-end sequencing run using MiSeq v3 chemistry gener-
ates approximately 25 million read pairs. Prior to genotyping anal-
ysis, MiSeq control software ﬁlters and discards 10–20% of the read
pairs due to poor imaging quality and about 5% are set aside into
special FASTQ ﬁles as unidentiﬁed reads with no recorded barcode
sequences. Thus, the total number of analyzable reads is approxi-
mately 20 million pairs. Theoretically, this number of reads should
translate into a run capacity of several thousand samples, but a
routine capacity is approximately 400 samples. Reduction in
capacity is due to biases causing an imperfect balance of targets
within the library, as well as the presence of non-target PCR
products.3. Results
3.1. Workﬂows
The workﬂows for the HLA class I and class II Version 3.0 geno-
typing kits are outlined with each discrete step in the process indi-
cated by a colored block for each reaction per sample, accompanied
by average timelines required for execution of the corresponding
steps (Fig. 1). In the class I workﬂow, there are nine amplicon
PCR reactions, which together generate targets for HLA-A/B/C
exons 1 through 7. After initial ampliﬁcations, the products are
pooled into three reactions per sample. After barcoding PCR, the
reactions are further consolidated into one tube in preparation
for the Illumina MiSeq loading procedure. For the HLA class II sys-
tem, each of 4 exons for HLA-DRB1, -DRB3, -DRB4, -DRB5, -DQA1,
-DQB1, -DPA1, -DPB1 are targeted in a total of 8 reaction mixes.
Amplicons were designed to include complete exons in all cases
except where primer binding sites are excluded from analysis
(Table 1).
Overlapping amplicons and database intersection were used for
coverage and phasing of exons in HLA class I (Fig. 2). For the kit
version used in this study (Table 1), exons 1 through 7 are
sequenced with phasing between a subset of amplicons provided
by alignment of overlapping positions that distinguish alleles. In
order to establish phase between exons 3 and 4 and between exons
5 and 6, a database intersection is implemented. This computa-
tional method, described below, calculates phase by comparing
the set of phased subsections of the genes with known genotypes
in the IMGT/HLA database (http://www.ebi.ac.uk/ipd/imgt/hla).3.2. Bioinformatics data analysis
The IGS data analysisworkﬂow, illustrated in Fig. 3, uses an auto-
mated typing application, GeMS-Analyzer, which exists within the
Amazon AWS framework that is also home to Illumina’s
BaseSpace. These applications are linked so that HLA data analysis
can be initiated via a BaseSpace account and no local computer pro-
cessors are required.Whendesired,GeMS-Analyzer is able to enlist a
multiplicity of virtual servers for parallelized computations in order
to reduce analysis times, e.g., 20 servers can process about 1 sam-
ple/min of HLA class I and class II data. When initiated by the IGS
user, GeMS-Analyzer accesses FASTQ ﬁles from BaseSpace, analyzes
them, and returns a typing results ﬁle to BaseSpace for user down-
load. This results ﬁle is then opened using the GeMS-HLA desktop
application for the IGS data viewing, editing, and reporting.
3.2.1. GeMS-Analyzer
Read pairs are packaged by the MiSeq control software into
FASTQ ﬁles, two per sample. Speciﬁcally, for each sample, all R1
are grouped into one FASTQ and the corresponding R2 are grouped
into a second FASTQ. Read identiﬁcation numbers are retained
within each FASTQ so that pairs can be analyzed together. The ﬁrst
step in GeMS-Analyzer processing is to dispose of read pairs con-
taining adaptor-dimers and chimeric PCR product sequences,
accounting for roughly 10–30% of the total read pairs per sample.
Adaptor-dimers and chimeras are identiﬁed using string searches
for forbidden sequences. In the second phase of analysis, reads
are subdivided into clusters according to loci and exons. This clus-
tering process uses string searches for primer sequences and other
motifs in order to allocate read pairs. The ﬁnal phase of analysis
involves independently comparing all read pairs in a given cluster
with a database of known alleles. For each cluster, the allele data-
base is composed of target exon sequences as well as non-target
pseudogenes from the IMGT database (http://www.ebi.ac.uk/ipd/
imgt/hla/) [39]. Upon each read pair comparison, the known allele
is given a matching score based on how well it is represented by
the read pair. The read comparison algorithm is based on the
Smith-Waterman [40] approach for pairwise alignments. After all
read pairs in a cluster have been processed, the allele database is
ranked by matching score. Using the top-ranked alleles, logical
operations are used to check these candidate sequences for chi-
meric PCR products, SNPs, allele drop-off, and novel alleles before
assigning a typing result.
3.2.2. GeMS-HLA
Typing reports generated by GeMS-Analyzer were reviewed and
edited using GeMS-HLA, an application for manual evaluation and
reporting of sequencing data. GeMS-Analyzer attaches warning
ﬂags to typing results in order to alert the user of results that need
veriﬁcation due to the presence of mismatched positions, low cov-
erage, PCR recombination products, and allele bias. For such cases,
GeMS-HLA allows a user to interrogate the ﬂagged results and edit
the report as necessary.
Amplicons that do not overlap cannot be phased by sequencing
and GeMS uses database intersection logic to infer phased
Fig. 1. IGS workﬂow schematic for HLA-class I and II Version 3 kits. Colored blocks represent the number of reactions per sample at each step. Technician and incubation
times are listed to the right of each step. In steps following barcode PCR, all samples are pooled together into tubes for further processing and MiSeq preparation. At the MiSeq
Prep step, libraries from class I, class II, and KIR may be pooled together for parallel sequencing.
Fig. 2. Gene coverage diagram corresponding to IGS HLA-class I Version 3. The gray
bars represent target amplicons, of which there are 7 per locus. Regions covered by
amplicons are phased by sequencing when overlapping regions contain one or more
positions that distinguish alleles. Genotypes are phased across regions not covered
by amplicons, i.e., introns 3 and 5, by database intersection logic within GeMS
software.
Fig. 3. Illustration of the cloud-based GeMS data pipeline for analyzing MiSeq reads
and delivering IGS sequencing results. (1) Upon MiSeq sequencing, data is streamed
to the IGS user’s BaseSpace account. (2) From the BaseSpace account, the user
launches GeMS-Analyzer. (3) GeMS-Analyzer generates a typing results ﬁle and
delivers it to BaseSpace, where is it available for download. (4) Once downloaded,
the results ﬁle is opened using the GeMS-HLA desktop application. GeMS-HLA is
then used for data validation and report generation.
W.C. Nelson et al. / Human Immunology 76 (2015) 928–938 931genotypes. In a heterozygous specimen, alleles A1 and B1 are two
alleles of exon 1, and A2 and B2 are two alleles of exon 2 generating
two possible pairwise combinations: A1A2 + B1B2 and
A1B2 + B1A2. If the available HLA database contains both of these
combinations, the result is diploid ambiguous. Alternatively, if
the database contains only one of these pairwise combinations,
the known combination is the most likely and ranked above the
unknown combination. GeMS-Analyzer has been designed to alsoconsider coverage levels, recombinant detection, and sequencing
quality in allele ranking. Importantly, an allele is equally likely to
be detected whether or not it exists in the database.
932 W.C. Nelson et al. / Human Immunology 76 (2015) 928–9383.3. IGS genotyping study
To demonstrate the system, 336 DNA samples were genotyped
using the IGS HLA class I and II Version 3.0 systems described in
Table 1. In order to test the versatility of the system, DNAs from
sources commonly encountered in CILs were tested including
blood, cell lines, buccal swabs, and blood spots. The samples were
processed in two separate MiSeq runs with each run using Illumina
v3 chemistry for 250-cycle paired-end sequencing and producing
20 million read pairs. In the ﬁrst run, the sequencing library con-
sisted of 95 whole blood and 51 LCL samples. The second library
consisted of 95 whole blood, 42 blood spot, and 53 buccal swab
samples. The second run also contained a library prepared using
the IGS Version 1.0 KIR haplotyping kit.
For each sample type and HLA locus, the total number of geno-
types is equal to twice the sample number, excepting the
HLA-DRB3, -DRB4, -DRB5 loci, which are present in linkage with
speciﬁc HLA-DRB1 alleles. The analysis process began with auto-
mated GeMS-Analyzer analysis followed by manual GeMS-HLA
data evaluation performed independently by two operators, who
reviewed ﬂagged results. Manual edits of ﬂagged results involved:
(i) coverage below 30 read pairs, (ii) allele biases, which were
ﬂagged when the coverage of one allele was larger than 4-fold that
of the other allele, and (iii) detection of a novel allele sequence
with high coverage at mismatched positions among the
top-ranked allele candidates.
The two edited GeMS-HLA reports were cross-checked for con-
sistency and the number of manual data edits was recorded
(Table 2). The ﬁnalized report was compared with reference panel
typing comprised of Sanger sequencing data from the IHWG and
the UCLA Immunogenetics Center. IGS results were checked for
concordance with reference types provided that they have cover-
age >20 over exons 2–4 in HLA class I and exons 2–3 in HLA class
II. This coverage criteria is consistent with other reports showing
that 20 coverage is a sufﬁcient minimum threshold for typing
accuracy [20,30] Genotypes missing data from those polymorphic
exons were deemed to have no data. Table S1 summarizes cover-
age data corresponding to the sequencing results in Table 2.
3.4. IGS typing accuracy
A comparison of all specimens having pre-existing ﬁelds 1:2 or
higher HLA typing data indicated 100% concordance with IGS data,
excepting three alleles listed in Table 3. For subject IHW09367, we
reported a homozygous DQB1⁄03:03:02, whereas the IHWG Cell
and DNA Bank record (http://www.ihwg.org) reports a heterozy-
gous DQB1⁄03:03:02 + 05:02:01. The same discrepancy was
observed in a previous report where alternate analysis was per-
formed [41] that conﬁrmed the typing reported here. For subject
IHW09377, the IHWG record lists DRB4⁄01:01:02, and we report
DRB4⁄01:01:01. In this case, it appears IHWG result was a typo-
graphical error because there is no record of DRB4⁄01:01:02 in
the IMGT/HLA database, past or present. Finally, for subject
IHW09385 we report DRB1⁄11:01:01 and the IHWG record con-
tains a DRB1⁄11:01:02. Wang et al. [20] described the same dis-
crepancy in their study, and conﬁrmed that the correct result is
DRB1⁄11:01:01 using Sanger sequencing as well as an alternative
NGS method.
No false positive results were observed in these samples, i.e., no
incorrect results that failed to be ﬂagged by GeMS-Analyzer. In
some instances, the typing results retained diploid ambiguities
that could not be resolved upon sequencing all target exons, e.g.,
the pairs DPB1⁄04:01:01/02 + 04:02:01/02 and DPB1⁄1
05:01 + 126:01 are not distinguished due to the inability to phase
between the two alternative combinations of exons 2 and 3. There
were a limited number of diploid ambiguities encountered in thisdataset as summarized in Table S2. Two similar diploid ambiguities
observed in DQB1 involved alleles with unknown exon sequences.
Speciﬁcally, DQB1⁄06:02:01 + 06:04:01 cannot be distinguished
from DQB1⁄06:39 + 06:84 based on the current database informa-
tion. In the same way, DQB1⁄06:02:01 + 06:09:01 and
DQB1⁄06:84 + 06:88 are indistinguishable.
Due to the extensive homology across the HLA genes, we
observed various pseudogenes, co-ampliﬁed with the target
sequences. A pseudogene sequence was detected in DQA1 exon 4
that prevented the IGS system from distinguishing DQA⁄01:0
4:01:01/02 and DQA1⁄01:05:02. Additionally, we observed several
apparent pseudogene sequences that match HLA alleles present in
the IMGT/HLA database. For example, the exon 2 sequence of the
DQB1⁄06:146 allele submitted to IMGT in April 2014 was detected
at a low level (approximately 20% coverage level compared with
the target) in all DQB1⁄06:02:01-positive samples. This study and
other work in our laboratory have ruled out contamination or other
sources of this sequence, suggesting that this allele sequence may
be derived from a pseudogene or other gene locus (e.g., -DQB2).
Also in this study, 21 samples were found to have a -DPA1 exon
3 variant sequence that matched DPA1⁄02:02:02 except for a C
instead of T at position 447. Beyond diploid ambiguities and pseu-
dogene interference, other allelic ambiguities remained due to
insufﬁcient read coverage at exons, e.g., low read pairs covering
B exon 1 prevented resolution of B⁄08:01:01 and B⁄08:01:20 in
subject IHW01154.
Four of the samples included in this study have a DQB1⁄04:01
allele according to external legacy typing results. Our results
revealed a discrepancy with the expected IMGT/HLA database
record in the exon 1 sequence for these alleles. Speciﬁcally, the
IGS-sequenced exon 1 for each of the four DQB1⁄04:01:01 alleles
examined included an A at position 79 of exon 1 (identical to
DQB1⁄04:02:01) rather than the G at this position reported in the
latest IMGT/HLA database. Read coverage data detected by
GeMS-Analyzer are listed in Table 4. These samples were heterozy-
gous in DQB1, including alleles DQB1⁄03:01, DQB1⁄02:01, and
DQB1⁄05:01, each of which has a distinguishing exon 1 sequence.
No other alleles were detected over exons 1–4 in these samples.
The exon 1 G reported for DQB1⁄04:01:01 is a unique sequence
among all DQB1 exon 1 sequences and, as such, somewhat suspect.
A reexamination of the original sample (LKT3/IHW9107) may be
required to determine if a sequencing error was reported or if
the four specimens in this study have novel -DQB1 alleles with
exon 1 sequences matching DQB1⁄04:02:01, and exons 2–4 match-
ing DQB1⁄04:01:01. The latter scenario was observed for subject
IHW09369, for which the IHWG database reports a homozygous
HLA-B⁄15:26N. Our results indicated that the exon 1 sequence
for this cell line matches B⁄15:01:01:01 instead, as shown in
Table 4. Wang et al. [20] also reported that this cell line possesses
a novel HLA-B allele in which exon 1 matches B⁄15:01:01:01 and
exons 2–7 match B⁄15:26N.3.5. DNA sources
The sample sets used for these analyses had a broad range of
DNA concentrations over the four sources tested, simulating spec-
imens that might be encountered in any genotyping laboratory.
HLA analysis showed that typing accuracy and exon coverage
(Tables 2 and S1) were largely independent of sample source and
DNA quantity. The number of read pairs per sample plotted over
a broad range of template DNA concentrations (0.6–96.3 ng/ll)
demonstrated that the balance of data per sample in the IGS
sequencing library was not sensitive to genomic DNA concentra-
tion (Fig. 4a), suggesting that the amplicon PCR reaches saturation
and has a normalizing effect.
Table 2
Results of IGS HLA genotyping study.
Sample source Samples # Conc. range (ng/ll) Results
Types # GeMS-HLA edits # (%) No data # (%) Concordance # (%) Resolutiona
CI ex 2–3 CI ex 2–4 CI ex 1–7
CII ex 2 CII ex 2–3 CII ex 1–4
Whole blood 190 5.9–96.3 A 190 13 (2.3) 1 189 (100) 189 (100) 189 (100) 182 (96.3)
B 190 1 189 (100) 189 (100) 186 (98.4) 185 (97.9)
C 190 1 189 (100) 189 (100) 188 (99.5) 178 (94.2)
DPA1 190 8 (0.7) 0 190 (100) 190 (100) 190 (100) 190 (100)
DPB1 190 1 189 (100) 189 (100) 189 (100) 181 (95.8)
DQA1 190 0 190 (100) 190 (100) 190 (100) 190 (100)
DQB1 190 1 189 (100) 189 (100) 189 (100) 186 (98.4)
DRB1 190 0 190 (100) 190 (100) 190 (100) 190 (100)
DRB345 183 0 183 (100) 183 (100) 183 (100) 172 (94.0)
Blood spot 42 n/a A 42 1 (0.7) 0 42 (100) 42 (100) 42 (100) 40 (95.2)
B 42 0 42 (100) 42 (100) 41 (97.6) 41 (97.6)
C 42 0 42 (100) 42 (100) 42 (100) 41 (97.6)
DPA1 42 3 (1.2) 0 42 (100) 42 (100) 42 (100) 42 (100)
DPB1 42 0 42 (100) 42 (100) 42 (100) 42 (100)
DQA1 42 0 42 (100) 42 (100) 42 (100) 42 (100)
DQB1 42 0 42 (100) 42 (100) 42 (100) 42 (100)
DRB1 42 0 42 (100) 42 (100) 42 (100) 42 (100)
DRB345 42 0 42 (100) 42 (100) 42 (100) 38 (90.5)
Buccal swab 53 0.6–40.0 A 53 4 (2.5) 0 53 (100) 53 (100) 53 (100) 47 (88.7)
B 53 0 53 (100) 53 (100) 53 (100) 50 (94.3)
C 53 0 53 (100) 53 (100) 53 (100) 47 (88.7)
DPA1 53 3 (0.9) 0 53 (100) 53 (100) 53 (100) 53 (100)
DPB1 53 0 53 (100) 53 (100) 53 (100) 51 (96.2)
DQA1 53 0 53 (100) 53 (100) 53 (100) 53 (100)
DQB1 53 0 53 (100) 53 (100) 53 (100) 53 (100)
DRB1 53 0 53 (100) 53 (100) 53 (100) 53 (100)
DRB345 52 0 52 (100) 52 (100) 52 (100) 49 (92.4)
LCL 51 1.1–22.1 A 51 4 (2.7) 0 51 (100) 51 (100) 51 (100) 48 (94.1)
B 51 0 51 (100) 51 (100) 51 (100) 50 (98.0)
C 51 0 51 (100) 51 (100) 51 (100) 46 (90.2)
DPA1 51 7 (2.4) 0 51 (100) 51 (100) 51 (100) 50 (98.0)
DPB1 51 0 51 (100) 51 (100) 51 (100) 50 (98.0)
DQA1 51 0 51 (100) 51 (100) 51 (100) 50 (98.0)
DQB1 51 0 50 (98.0) 50 (100) 50 (100) 49 (98.0)
DRB1 51 0 50 (98.0) 50 (100) 50 (100) 49 (98.0)
DRB345 49 0 48 (97.9) 48 (100) 48 (100) 47 (97.9)
a Instances of diploid and allele ambiguities are listed in Table S2.
Table 3
HLA study non-concordant results.
Cell line IMGT record This study Comments
IHW09367 DQB1⁄03:03:02 + DQB1⁄05:02:01 DQB1⁄03:03:02 + DQB1⁄03:03:02 Resolved by external typing:
Wittig et al. [41] report homozygous DQB1⁄03:03:02, obtained by an alternative NGS
method. Homozygous DQB1⁄03:03:02 is also reported in the protocol of a commercial
SSP-based HLA-DQ Typing kit (GeneBox, Cantanhede, Portugal)
IHW09377 DRB3⁄02:02:01 + DRB4⁄01:01:02 DRB3⁄02:02:01 + DRB4⁄01:01:01 Prior result is a typo:
DRB4⁄01:01:02 is not found in the IMGT database
IHW09385 DRB1⁄01:01 + DRB1⁄11:01:02 DRB1⁄01:01:01 + DRB1⁄11:01:01 Previously resolved by Wang et al. [21]:
DRB⁄11:01:01 and 11:01:02 are distinguished by A versus G at position 357 in exon 2.
This study detected no evidence of a G at that position, and Wang et al. obtained the
same result by Sanger and an alternative NGS method
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To examine allele bias across all exons and loci, heterozygous
genotypes were plotted as relative coverage, i.e., the ratio of allele
1 to allele 2, where allele 1 has fewer reads (Fig. 4b and c). With
this deﬁnition a perfectly balanced PCR has a relative coverage of
1. The data indicated that a signiﬁcant majority of loci exhibited
relative coverage of greater than 0.5, and in the worst cases was
near 0.2. As a result, GeMS-Analyzer is designed to alert the user
to data with relative coverage less than 0.25. Allele imbalance is
also detected in GeMS-Analyzer by checking for consistency acrossall exons using database intersection logic. For example, if allele
drop-off at one exon leads to a homozygous result where a
heterozygous result would be consistent with genotypes in the
IMGT/HLA database, the result is ﬂagged for user evaluation in
GeMS-HLA. In a single exception due to the complete divergence
of intron 2 sequences for the B⁄73:01 and B⁄73:02 alleles,
GeMS-Analyzer uses a special case analysis algorithm to assemble
a complete exon 2 in addition to relying on data from exons 1, 3–7
and partial data from exon 2 assembled via the general case anal-
ysis algorithms. Among the 336 samples analyzed, 3 samples with
B⁄73:01 were correctly genotyped.
Table 4
Discrepant exon 1 IMGT database record.
Sample Legacy result GeMS candidate allele Read pair coverage
Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7
PL1–28 DQB1⁄04:01 DQB1⁄04:01:01 0a 283 484 142 – – –
DQB1⁄04:02:01 103 0 484 142 – – –
PL2–30 DQB1⁄04:01 DQB1⁄04:01:01 0a 144 215 45 – – –
DQB1⁄04:02:01 40 0 215 45 – – –
PL2–52 DQB1⁄04:01 DQB1⁄04:01:01 0a 143 243 74 – – –
DQB1⁄04:02:01 31 0 243 74 – – –
PL3–70 (IHW09370) DQB1⁄04:01 DQB1⁄04:01:01 0a 46 434 93 – – –
DQB1⁄04:02:01 45 0 434 93 – – –
PL3–69 (IHW09369) B⁄15:26N B⁄15:26N 0a 817 771 253 154 1101 590
B⁄15:01:01:01 91 0 0 253 154 1101 590
a Coverage = 0 due discrepancy with IMGT database record for exon 1 sequence.
Fig. 4. (a) Normalized read pair counts for IGS libraries from different DNA sources versus amplicon PCR template concentration. N = number of samples in each library. For
an ideal balance of reads per sample, all normalized read pair counts would be equal to 1. (b) Class I relative allele coverage calculated for all heterozygous samples (total
allele pairs for each box plot: exons 1–2–3/4–5/6–7: A = 732/506/244, B = 781/362/124, C = 690/475/115) as the ratio of the read pairs for allele 1 to allele 2, where the
numerator allele has lower coverage. Boxes represent median and interquartile ranges, whiskers show range, and outliers are plotted separately as dots. (c) Class II relative
allele coverage calculated for all heterozygous samples (total allele pairs for each box plot: exon 1/2/3/4: DPA1 = 0/144/134/117, DBP1 = 0/250/176/93, DQA1 = 248/267/265/
270, DQB1 = 212/275/271/236, DRB = 300/469/430/147); plotted in the same manner as (b).
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A selection of specimens to validate the detection of null alleles
including A⁄68:11N, C⁄04:09N, and DRB5⁄01:08N were examined
in this study. Cell lines IHW09418 and IHW09419 were correctly
typed as A⁄68:11N, which is distinguished from A⁄68:01 by posi-
tions in exon 1, i.e., a single base deletion at position 46 and a T
at position 47. The cell line IHW09501 was correctly typed as
C⁄04:09N based on the single base deletion at position 1095 in
exon 7. This report also included the detection in 4 specimens hav-
ing the 19 base exon 3 deletion that characterizes the
DRB5⁄01:08N allele.
As described above (Fig. 2), the HLA class I system covers intron
sequences that can be utilized for null allele detection inGeMS-Analyzer. For example, B⁄15:01:01:02N is distinguished
from the wild type by a 10-base deletion at position 175 of intron
1. Similarly, A⁄24:02:01:02L is detected by a substitution at posi-
tion 708 in intron 2. One LCL specimen (IHWG09504) was typed
in this study to demonstrate the accurate detection of
A⁄24:02:01:02L. In total, sequences identifying all 8-digit HLA-A
and HLA-B alleles reported in the IMGT v.3.19 with the N, L, or S
designation, excepting HLA-A⁄02:01:01:02L, can be detected by
the IGS and reported by GeMS-Analyzer (Table S3).
3.8. IGS KIR haplotyping
One of the advantages of the amplicon-based NGS approach for
genotyping is its extensibility to other genetic loci without
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haplotyping protocol previously described [42] using sequencing
with ABI dye terminators was adapted to the IGS system, querying
KIR exons 3, 4, 5 and 9 for gene content. Whereas the dye termina-
tor protocol depended on ﬂuorescent peak heights of variant posi-
tions marking speciﬁc KIR loci, the IGS protocol utilizes direct
counting of relative read numbers from KIR loci-speciﬁc amplicons
ampliﬁed with the same primer pairs. Those locus-speciﬁc
sequences measured in the dye terminator protocol were queried
using this NGS approach, and additional locus-speciﬁc sequences
from exons 5 and 9 were incorporated into the analysis algorithm
to provide further conﬁrmation.
The commercially available KIR IGS kit v1.0, which determines
haplotype content in the manner described above, was used on
81 blood and 12 LCL samples. Positive controls included 24 sam-
ples that had been previously KIR typed for gene content or
sequenced in their entirety [42,43]. The workﬂow employed essen-
tially the same steps carried out for HLA class I or class II (Fig. 1),
with 4 amplicon PCR reactions followed by consolidation into
one reaction per sample for barcoding. Samples were pooled and
run together with HLA class I and class II libraries on the same
MiSeq run. The current version of KIR analysis software measures
gene content through string searches and includes partial allelic
data. A KIR IGS version enabling complete allele determination
using the GeMS-Analyzer/GeMS-HLA framework is under
development.
For 93 samples, data were recovered for all targeted exons, all
samples yielded complete haplotype data, and all detected pat-
terns matched previously identiﬁed KIR haplotypes (Table S4). A
representative variety of KIR haplotypes with frequencies similar
to those found in previous studies [42] were detected (Table 5).
All 24 positive control samples yielded haplotypes concordant with
previous studies. The samples examined are commonly available
samples (i.e., from UCLA panels, IHWG panels) and therefore these
data may ﬁnd utility as a comparative dataset in other studies. The
capacity to include KIR haplotyping with HLA in parallel demon-
strated the capability for expansion of the IGS to other complex
genetic systems in an entirely horizontal fashion, capitalizing on
the previously developed HLA components including the protocol,
workﬂow, and analysis frameworks.4. Discussion
As interest in NGS for genotyping HLA and other genetic sys-
tems continues to grow, there is little doubt that the technology
will soon move aggressively into clinical immunogenetics labora-
tories supporting HCTs. This study demonstrated the use and capa-
bilities of an integrated genotyping system using amplicon-based
NGS approaches for HLA and KIR genotyping, and has deﬁned chal-
lenges to be met and improvements to be made that can accelerate
this transition. The approach demonstrated the ability to generate
high-resolution genotypes from a variety of DNA sources common
to research and clinical genotyping applications. The protocols,
reagents, and software applications are commercially available
and are now being used in CILs and for research in support of vac-
cine trials [44,45].
In designing the IGS laboratory workﬂow, amplicon PCR was
chosen as the target generation mechanism for a number of rea-
sons. First, it is generally applicable to any locus, with the design
of new genotyping assays constrained primarily by the existence
of adequate genomic data resources. As genome sequence data
accumulates rapidly [46,47], we expect that this limitation, to
the extent that it exists, will be short-lived, even for the more chal-
lenging genomic regions that are equivalent in complexity to the
MHC and KIR. The data analysis approach and software toolsapplied are also extensible if genomic data resources are available
by the use of rule sets for assignment of allele types. This extensi-
bility enables the IGS to support and expand into new areas for
genotyping with relative ease using the established framework
for genotyping the HLA system, itself among the most complex
and polymorphic genetic systems.
A second and technical advantage of amplicon-based NGS for
CILs in particular is the simplicity of application. The basic
approach includes amplicon PCR and incubation steps that are
already in common use in CILs, and avoids steps that involve vari-
able interpretations and adjustments in protocol, such as random
fragmentation of larger DNA products or gel extraction for size
selection. This is a notable advantage given the needs of CILs to
provide results in a time-constrained setting, with the associated
low tolerance for sample repeats. A third advantage is the high tol-
erance for DNA sources and concentrations with as little as 20 ng of
total DNA sufﬁcient for the complete six-digit HLA class I and class
II eleven locus typing reported here (Fig. 4). This is an essential
consideration in particular given variability in both quality and
quantity of DNA derived from common sample sources available
to clinical laboratories. Quality of DNA is a consideration for DNA
from blood spots, and to a lesser extent from buccal swabs, which
may provide DNA below of the size range suitable for long range
PCR.
In addition to their application in the CIL setting,
amplicon-based approaches are applicable in medium and high
throughput settings as well. The bulk of each workﬂow involves
setting up and then transferring and aggregating PCR reactions
and products. Given the availability of pipetting robotics that can
perform these tasks, several satisfactory alternatives for equipping
a laboratory with a high throughput workﬂow system can be envi-
sioned. As a pointed example, the entirety of the HLA and KIR geno-
typing reported in this study – without any supporting robotics –
was prepared for two MiSeq runs by one technician within 2 weeks
(average times required for each step are indicated in Fig. 1).
An advantage of long-range (LR) PCR shotgun approaches over
amplicon-PCR is the completeness of the DNA sequences obtained.
While LR-PCR provides intron sequences, it is not at all clear that
such data will have any impact in the HCT or other settings beyond
the identiﬁcation of new – and at this point rare – intron-encoded
null or otherwise functionally altered alleles. Indeed, the most
effective application of the LR approach may be in generating geno-
mic sequences that supplement databases to further enhance
amplicon-based approaches. Given that the majority of the varia-
tion in HLA lies in exons 2 and 3 of HLA class I and exon 2 of the
HLA class II genes, intron-encoded polymorphism is relatively
lower in extent [48] and even more so in functional consequence
[49]. At the same time, the amplicon approach can effectively iden-
tify intron-encoded null alleles (Table S3) by capturing introns 1, 2,
4, and 6 in HLA class I (Fig. 2), and could be easily extended to
include all HLA class I intron data if that proved useful. Another
proposed advantage of the LR approach is the ability to phase data
more completely and thus to lower the number of diploid ambigu-
ities reported. However, this is apparently of minimal impact given
the small number of diploid ambiguities remaining when sequenc-
ing HLA class I exons 1–7 and HLA class II exons 1–4 using the
amplicon approach. In fact, of the diploid ambiguities that do
remain, most of these persist with shotgun approaches when alle-
les share common sequences extending longer than the average
sequence extent generated by the sequencing technology (e.g.,
the distance between exons 2 and 3 is 2500 bp for HLA-DQB1
and 4000 bp for HLA-DPB1). The only technology capable of
resolving such ambiguities may be the single molecule real time
sequencing approach from Paciﬁc Biosciences [50], to the extent
that this method can be routinely applied to HLA.
Table 5
Results of IGS KIR haplotyping study.
Sample source Samples # Conc. range (ng/ll) Results
Haplotypes detecteda # (Frequency)
Whole blood 81 6.7–13.3 cA01|tA01 + cA01|tA01 19 (0.23)
cA01|tA01 + cA01|tB01 10 (0.12)
cA01|tA01 + cA01|tB01  del7 1 (0.01)
cA01|tA01 + cB01|tA01 9 (0.11)
cA01|tA01 + cB01|tA01  hybd1 1 (0.01)
cA01|tA01 + cB01|tA01  hybd2 1 (0.01)
cA01|tA01 + cB01|tA01  ins4 1 (0.01)
cA01|tA01 + cB01|tB01/cA01|tB01 + cB01|tA01 5 (0.06)
cA01|tA01 + cB02|tA01 6 (0.07)
cA01|tA01 + cB02|tB01/cA01|tB01 + cB02|tA01 9 (0.11)
cA01|tA01 + cB02|tB01  del6 4 (0.05)
cA01|tA01  del5 + cB01|tA01  del10 1 (0.01)
cA01|tA01  ins4 + cA01|tB01 1 (0.01)
cA01|tB01 + cA01|tB01 2 (0.02)
cB01|tA01 + cB01|tA01 1 (0.01)
cB01|tB01 + cB02|tA01/cB01|tA01 + cB02|tB01 1 (0.01)
cB02|tA01 + cB01|tA01 2 (0.02)
cB02|tA01 + cB01|tA01  hybd1 1 (0.01)
cB02|tA01 + cB02|tA01 1 (0.01)
cB02|tA01 + cB02|tB01 1 (0.01)
LCL 12 2.4–16.2 cA01|tA01 + cB01|tA01 2 (0.17)
cA01|tA01 + cB01|tA01  hybd2 1 (0.08)
cA01|tA01 + cB01|tB01/cA01|tB01 + cB01|tA01 2 (0.17)
cA01|tA01 + cB02|tA01 3 (0.25)
cA01|tA01 + cB02|tB01/cA01|tB01 + cB02|tA01 3 (0.25)
cA01|tB01  del8 + cB02|tA01 1 (0.08)
a KIR haplotype nomenclature codes from [43] available in Table S4.
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In an amplicon-based approach, as with other NGS systems, the
primary goal of the laboratory preparation protocol is to produce a
well-balanced sequencing library, ideally one in which every target
is equally represented. The key challenge is maximizing the num-
ber of targets per reaction while minimizing preferential ampliﬁca-
tion. Given 20 million reads and completely balanced
ampliﬁcations of all targets, the theoretical number of typings
per MiSeq run is over 10,000 samples. In practice, 400 samples
per run is routinely achievable, with the differential being largely
due to imbalances between different amplicons, and the need to
capture the lowest frequency product among them. This requires
that the average read number is closer to 500 copies lowering
the potential typeable number to 1000 samples, with the remain-
der of the reduction due to primer dimer and chimeric reads that
are eliminated by the software. While there is substantial room
for increasing the sample count per run by better balancing of
the amplicon reaction products, 400 samples per run fares very
well against other approaches and is about 5-fold the routine
throughput of typical CILs.4.2. Improvements in software
The main area for development and optimization within the
data analysis mechanism of the IGS is to reduce the number of
ﬂagged results per run, thereby reducing the amount of time spent
by an operator evaluating data in GeMS-HLA. Ideally, there would
only be ﬂags to indicated failed typings due to the absence of a
valid read pair population. Given the complexity and diversity of
HLA libraries however, in this study and routinely, many ﬂags
(approximately 0.5 ﬂags per sample) result because the primary
focus has been on designing GeMS-Analyzer to be fault-tolerant
– meaning that low coverage, high allele bias, novel alleles, and
interference from non-target read pairs leads to ﬂagged results
beyond any false positives. Ultimately, this fault-tolerant designcan be optimized through improvements in the operational match-
ing statistics that allow quantitative measures of conﬁdence to be
established for each genotype. This iterative optimization process
involves cycles of building more effective logic and testing it on
large and diverse datasets. Additionally, the implementation of
an independent parallel analysis algorithm within
GeMS-Analyzer for crosschecking the current algorithm can pro-
vide additional conﬁdence in establishing well-founded statistical
probabilities.
Another key component for advancing GeMS-Analyzer is to
incorporate new data into further building and reﬁning the allele
databases. Already, the number of new allele sequences added to
the IMGT/HLA and other reference databases is rapidly expanding,
primarily due to the application of NGS to build large HLA typing
repository data [25]. With this expansion, however, care must be
taken in ensuring that these submissions are accurate and thor-
oughly characterized by independent methods. In our experience,
co-ampliﬁed pseudogene sequences or other derivative sequence
targets are the main source of interference in HLA typing by NGS,
and a fault-tolerant design is required to prevent misinterpreting
a pseudogene or chimeric PCR product as the target allele. Going
forward, the current software architecture of GeMS-Analyzer
allows for the capture and accumulation of frequency data on all
alleles genotyped, which in turn will contribute to probability esti-
mates and establishment of more powerful databases in support of
genotyping. While the IMGT/HLA database is well established and
largely complete beyond the addition of novel rare alleles, this
approach can have a signiﬁcant impact on the rapid establishment
of new allele databases in support of other gene systems, such as
KIR and others of potential immunological consequence [51].4.3. Clinical use of the IGS
The IGS was developed to enable low- to mid-throughput clin-
ical laboratories to utilize NGS and drive progress in precision
medicine [52,53]. This transition will build upon a long history of
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will have the opportunity to adopt NGS for HLA by using the IGS
and similar systems. Longer term opportunities presented by
NGS include broadening the scope of precision medicine in CILs
well beyond HLA. The laboratory and computational components
of the IGS were designed to facilitate this process, enabling clinics
to perform new genetic tests without having to install a new work-
ﬂow, which by itself can be prohibitive in a smaller CIL setting. An
NGS device such as the Illumina MiSeq can serve as a genetic test-
ing platform that can generate a variety of results, in some ways
analogous to a computer operating system on which diverse soft-
ware programs can run. Furthering the analogy, the IGS is designed
to be an expandable suite of programs, each providing a different
genetic test result. For example, when coupled with the IGS a
MiSeq run can be used to simultaneously obtain HLA and KIR data
as this study demonstrated. This consolidation of genetic testing
platforms is applicable to the typing of virtually any genetic locus
including a variety of assays such as chimerism and minimal resid-
ual disease [54,55].
Through the use of NGS, CILs may play a central role in not only
developing more effective donor–recipient matching criteria based
on HLA and other immune loci, but also extending precision med-
icine beyond HCTs into treatments for other diseases. While the
IGS is innovative in the CIL environment, the CILs themselves have
been innovating in clinical medicine for decades. HLA typing
advancements and corresponding improvements in HCT outcomes
would simply not have arrived at the present state without the
innovations brought to fruition by the CILs supporting HCTs in col-
laboration with clinical scientists. These partnerships have proven
to be extremely effective in advancing the state of HLA typing and
chimerism testing and revealing new outcome correlations. By
providing these laboratories and their respective clinical environ-
ments with the ability to reduce costs and at the same time expand
the repertoire of genetic testing, additional improvements to clin-
ical outcomes are likely to come. The extensibility of
amplicon-based protocols facilitates the ready addition of new
gene testing components. The overall efﬁciency and ease of use
of the general approach can be maintained, allowing CILs to partic-
ipate in new genotyping applications without disrupting routine
operations. Given this capability, physicians will be more likely
to include novel tests in their clinical research protocols in order
to meet emerging needs, and thereby accelerate the development
of precision medicine.Conﬂict of interest
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